JANX Janux Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: JANX

Price (delayed)

$13.77

Market cap

$839.75M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.84

Enterprise value

$808.68M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 33
Highlights
The revenue has grown by 47% YoY and by 37% from the previous quarter
JANX's gross profit is up by 47% YoY and by 37% QoQ
The quick ratio has dropped by 71% year-on-year and by 56% since the previous quarter
The net income has contracted by 47% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of JANX

JANX stock price

How has the Janux Therapeutics stock price performed over time
Intraday
1.32%
1 week
-6.58%
1 month
-4.51%
1 year
-45.2%
YTD
-0.22%
QTD
-0.94%

Financial performance

How have Janux Therapeutics's revenue and profit performed over time
Revenue
$13.73M
Gross profit
$13.73M
Operating income
-$156.98M
Net income
-$114.48M
Gross margin
100%
Net margin
-833.6%
The revenue has grown by 47% YoY and by 37% from the previous quarter
The net income has contracted by 47% YoY
JANX's gross profit is up by 47% YoY and by 37% QoQ
JANX's operating income is down by 38% year-on-year

Price vs fundamentals

How does JANX's price correlate with its fundamentals

Growth

What is Janux Therapeutics's growth rate over time

Valuation

What is Janux Therapeutics stock price valuation
P/E
N/A
P/B
0.89
P/S
62.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
58.89
The EPS has contracted by 36% YoY
JANX's P/B is 54% below its 5-year quarterly average of 1.9 and 27% below its last 4 quarters average of 1.2
JANX's equity is down by 7% year-on-year
The P/S is 93% less than the last 4 quarters average of 889.5 and 79% less than the 5-year quarterly average of 301.5
The revenue has grown by 47% YoY and by 37% from the previous quarter

Efficiency

How efficient is Janux Therapeutics business performance
The ROS has grown by 27% from the previous quarter
JANX's return on equity is down by 27% year-on-year and by 2.6% since the previous quarter
The ROA has contracted by 26% YoY
The return on invested capital has declined by 14% year-on-year

Dividends

What is JANX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JANX.

Financial health

How did Janux Therapeutics financials performed over time
The total liabilities has soared by 126% YoY and by 94% from the previous quarter
The quick ratio has dropped by 71% year-on-year and by 56% since the previous quarter
Janux Therapeutics's debt is 98% lower than its equity
JANX's equity is down by 7% year-on-year
Janux Therapeutics's debt has decreased by 4.6% YoY and by 2.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.